The new vaccine against David-19 in the form of a leukemia, the first Switzerland to test it

According to Swiss media, the vaccine of the new generation functions with a principle different from actual vaccines and does not use mRna.

The medicine aims to promote cell immunity and not the production of antibodies by relying on lymphocytes to eliminate virus-infected cells and prevent them from reproduced.

This is a supplementary vaccine of existing vaccines and is not intended to replace them,” said Alix Miauton, head of clinical test.

“Objective of the” experiment, he explained, “is to determine whether the vaccine is safe and does not cause serious side effects. ”

Each of the 326 volunteers who receive the vaccine will be followed in six months, and in the first phase, the vaccine will not be shaped like a leukemia, but will be administered using microgilpa, writes Ora News.

The first results will be available in June, and if clinical trials of phases 1, 2 and 3 produce satisfactory results then the final vaccine will be available no sooner than 2025, writes Tg Com.